Executives from Edgewise Therapeutics (NASDAQ:EWTX) highlighted recent clinical updates and upcoming milestones across the ...
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Treatment with EDG-5506 resulted in significant ...
U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases Capricor remains on track for the August 31, ...
– Company to host an Industry Forum to discuss the lived experience of Becker and clinical advancements featuring a leading neuromuscular disease expert and a patient advocate – Edgewise is sponsoring ...
Posters will be showcased at various times throughout the day in the Exhibit Hall. The full MDA 2026 Conference program is available at mdaconference.org. The Edgewise presentation and posters will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results